TABLE 1

Patient Demographics and Clinical Characteristics

Baseline, September 2014 to August 2016, n = 69Intervention, September 2016 to December 2017, n = 60P
Patient demographics and clinical characteristics, n (%)
 Girls24 (34.8)23 (38.3).676
 Age, y7.1 (4.5)7.4 (4.4).680
 Maximum HASS score9.7 (1.5)9.3 (1.6).153
 HASS score on admission8.5 (1.6)8.4 (1.8).774
 Continuous albuterol use, ha2.4 (2.0)4.4 (4.0).002
Outcomes and balancing measures, mean (SD)
 LOS, ha40.4 (21.9)31.9 (17.0).029
 Time to q4h albuterol administration, ha27.5 (11.3)17.4 (7.8)<.001
 Transfer to Boston Children’s Hospitala19 (27.5)7 (11.7).025
 HASS score at transfer9.8 (1.6)10.3 (1.6).514
 ICU therapy at South Shore Hospital5 (7.3)1 (1.7).215
 72-h bounce back2 (2.9)0 (0.0).499
  • a Meets clinical significance at P < .05.